S Middle for Biotechnology headed by Professor Dr.

This costly project was only possible because of a cooperation between Bielefeld University and its own international project companions. The researchers have finally published their results in the internationally renowned scientific journal 'Character Biotechnology'. To carry out this task, the CeBiTec research group cooperated with the University of Natural Resources and Lifestyle Sciences in Vienna , the Austrian Center of Industrial Biotechnology , and two pharmaceutical businesses: Novartis and Pfizer . Professor Dr. Thomas Noll, Scientific Director of CeBiTec, is confident that the info they have obtained will be of great interest to science and market.Kereiakes, M.D., Medical Director at The Christ Medical center Heart and Vascular Middle and The Lindner Study Center in Cincinnati, Ohio and a principal investigator for the Taxus Perseus scientific trial analyzing the Taxus Component Stent. The Component Stent series is supposed to provide a complete selection of DES solutions for interventional cardiologists, providing them with the option to take care of individuals with a paclitaxel, everolimus or bare-metal stent.